Logo image of PACB

PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Fundamental Analysis

USA - NASDAQ:PACB - US69404D1081 - Common Stock

1.76 USD
-0.02 (-1.12%)
Last: 11/7/2025, 8:06:40 PM
1.79 USD
+0.03 (+1.7%)
After Hours: 11/7/2025, 8:06:40 PM
Fundamental Rating

2

Overall PACB gets a fundamental rating of 2 out of 10. We evaluated PACB against 58 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of PACB have multiple concerns. PACB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PACB has reported negative net income.
In the past year PACB has reported a negative cash flow from operations.
PACB had negative earnings in 4 of the past 5 years.
In the past 5 years PACB reported 4 times negative operating cash flow.
PACB Yearly Net Income VS EBIT VS OCF VS FCFPACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

The Return On Assets of PACB (-63.76%) is worse than 86.21% of its industry peers.
PACB has a Return On Equity of -856.02%. This is amonst the worse of the industry: PACB underperforms 91.38% of its industry peers.
Industry RankSector Rank
ROA -63.76%
ROE -856.02%
ROIC N/A
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
PACB Yearly ROA, ROE, ROICPACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 24.00%, PACB is doing worse than 77.59% of the companies in the same industry.
PACB's Gross Margin has declined in the last couple of years.
PACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
PACB Yearly Profit, Operating, Gross MarginsPACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

PACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PACB has been increased compared to 1 year ago.
The number of shares outstanding for PACB has been increased compared to 5 years ago.
The debt/assets ratio for PACB is higher compared to a year ago.
PACB Yearly Shares OutstandingPACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
PACB Yearly Total Debt VS Total AssetsPACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -5.50, we must say that PACB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PACB (-5.50) is worse than 84.48% of its industry peers.
A Debt/Equity ratio of 10.51 is on the high side and indicates that PACB has dependencies on debt financing.
The Debt to Equity ratio of PACB (10.51) is worse than 93.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.51
Debt/FCF N/A
Altman-Z -5.5
ROIC/WACCN/A
WACC7.29%
PACB Yearly LT Debt VS Equity VS FCFPACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

PACB has a Current Ratio of 6.92. This indicates that PACB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 6.92, PACB belongs to the best of the industry, outperforming 87.93% of the companies in the same industry.
A Quick Ratio of 6.02 indicates that PACB has no problem at all paying its short term obligations.
The Quick ratio of PACB (6.02) is better than 86.21% of its industry peers.
Industry RankSector Rank
Current Ratio 6.92
Quick Ratio 6.02
PACB Yearly Current Assets VS Current LiabilitesPACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for PACB have decreased strongly by -50.00% in the last year.
The Revenue for PACB has decreased by -23.19% in the past year. This is quite bad
Measured over the past years, PACB shows a quite strong growth in Revenue. The Revenue has been growing by 11.12% on average per year.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)-23.19%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%-3.82%

3.2 Future

Based on estimates for the next years, PACB will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.41% on average per year.
Based on estimates for the next years, PACB will show a quite strong growth in Revenue. The Revenue will grow by 14.38% on average per year.
EPS Next Y-0.38%
EPS Next 2Y29.05%
EPS Next 3Y19.56%
EPS Next 5Y12.41%
Revenue Next Year3.4%
Revenue Next 2Y9.12%
Revenue Next 3Y12.77%
Revenue Next 5Y14.38%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PACB Yearly Revenue VS EstimatesPACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
PACB Yearly EPS VS EstimatesPACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PACB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PACB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PACB Price Earnings VS Forward Price EarningsPACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PACB Per share dataPACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PACB's earnings are expected to grow with 19.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.05%
EPS Next 3Y19.56%

More info and screens

0

5. Dividend

5.1 Amount

PACB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACIFIC BIOSCIENCES OF CALIF

NASDAQ:PACB (11/7/2025, 8:06:40 PM)

After market: 1.79 +0.03 (+1.7%)

1.76

-0.02 (-1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-11 2026-02-11/amc
Inst Owners57.25%
Inst Owner Change-0.16%
Ins Owners0.98%
Ins Owner Change-0.28%
Market Cap528.65M
Revenue(TTM)154.01M
Net Income(TTM)-526.36M
Analysts75.29
Price Target2.08 (18.18%)
Short Float %12.49%
Short Ratio4.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-313.85%
Min EPS beat(2)-646.96%
Max EPS beat(2)19.26%
EPS beat(4)2
Avg EPS beat(4)-189.42%
Min EPS beat(4)-646.96%
Max EPS beat(4)19.26%
EPS beat(8)3
Avg EPS beat(8)-114.36%
EPS beat(12)4
Avg EPS beat(12)-75.63%
EPS beat(16)5
Avg EPS beat(16)-58.32%
Revenue beat(2)2
Avg Revenue beat(2)4.48%
Min Revenue beat(2)3.35%
Max Revenue beat(2)5.6%
Revenue beat(4)2
Avg Revenue beat(4)-0.48%
Min Revenue beat(4)-6.61%
Max Revenue beat(4)5.6%
Revenue beat(8)3
Avg Revenue beat(8)-1.93%
Revenue beat(12)6
Avg Revenue beat(12)0.24%
Revenue beat(16)7
Avg Revenue beat(16)0.1%
PT rev (1m)1.88%
PT rev (3m)4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.36%
EPS NY rev (1m)4.09%
EPS NY rev (3m)-10.64%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)2.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.39
P/FCF N/A
P/OCF N/A
P/B 8.6
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.19
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.52
BVpS0.2
TBVpS-0.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.76%
ROE -856.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24%
FCFM N/A
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
F-Score2
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 10.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.89%
Cap/Sales 4.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.92
Quick Ratio 6.02
Altman-Z -5.5
F-Score2
WACC7.29%
ROIC/WACCN/A
Cap/Depr(3y)69.29%
Cap/Depr(5y)60.46%
Cap/Sales(3y)7.21%
Cap/Sales(5y)5.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y-0.38%
EPS Next 2Y29.05%
EPS Next 3Y19.56%
EPS Next 5Y12.41%
Revenue 1Y (TTM)-23.19%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%-3.82%
Revenue Next Year3.4%
Revenue Next 2Y9.12%
Revenue Next 3Y12.77%
Revenue Next 5Y14.38%
EBIT growth 1Y-77.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.57%
EBIT Next 3Y20.23%
EBIT Next 5Y15.78%
FCF growth 1Y42.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3YN/A
OCF growth 5YN/A

PACIFIC BIOSCIENCES OF CALIF / PACB FAQ

What is the ChartMill fundamental rating of PACIFIC BIOSCIENCES OF CALIF (PACB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PACB.


What is the valuation status for PACB stock?

ChartMill assigns a valuation rating of 0 / 10 to PACIFIC BIOSCIENCES OF CALIF (PACB). This can be considered as Overvalued.


Can you provide the profitability details for PACIFIC BIOSCIENCES OF CALIF?

PACIFIC BIOSCIENCES OF CALIF (PACB) has a profitability rating of 0 / 10.


What is the expected EPS growth for PACIFIC BIOSCIENCES OF CALIF (PACB) stock?

The Earnings per Share (EPS) of PACIFIC BIOSCIENCES OF CALIF (PACB) is expected to decline by -0.38% in the next year.